At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
PXL065 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients
In Brief
A Phase 2 clinical trial evaluating PXL065 and Placebo oral tablet for NASH - Nonalcoholic Steatohepatitis. Completed, enrolled 117 participants across 29 sites.
Detailed Summary
This study will assess the effect of 3 doses of PXL065 versus placebo on liver fat content in NASH patients after 36 weeks of treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNASH - Nonalcoholic Steatohepatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartSep 2020
Primary CompletionJun 2022
Study CompletionJun 2022
TodayJul 2026
First PostedMar 25, 2020
Enrollment StartSep 1, 2020
Primary CompletionJun 8, 2022
Study CompletionJun 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.3 years ago
Interventions
PXL065drug
PXL065 oral tablet
Placebo oral tabletdrug
Placebo oral tablet